Final patient treated in PolyNovo BTM trial
30 July, 2013 by Dylan Bushell-EmblingPlastic surgeons have completed treatment for the last of 10 patients enrolled in a trial of PolyNovo’s NovoSorb BTM in free-flap donor site repair surgery.
Consegna picks manufacturer for nasal dilator
30 July, 2013 by Dylan Bushell-EmblingConsegna (ASX:CGP) has chosen ChinaMed as its global manufacturing partner for Turbine, a nasal dilator product bound for the Australian sporting goods market.
Phosphagenics moving to phase II for TPM/oxycodone
29 July, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) will move on to phase II trials of its oxycodone patch product, after demonstrating sustained delivery in phase I.
Opportunities for Australian biotechs in Switzerland
29 July, 2013 by Susan WilliamsonGeneva-based Campus Biotech is open to Australian biotech companies interested in establishing offices of R&D facilities in Europe.
Phylogica and Cubist team up to evaluate antimicrobial Phylomers
26 July, 2013Peptide drug discovery company Phylogica (ASX: PYC) is collaborating with US-based Cubist Pharmaceuticals (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multidrug-resistant bacterial infections.
Registrations open for Australia’s premier biotech investment and capital raising event
25 July, 2013AusBiotech and Beacon Events have joined forces to launch Australia’s premier event for biotech investment and capital raising - Australia Biotech Invest.
QRxPharma collaborates with Aesica
24 July, 2013Melbourne-based biopharmaceutical company QRxPharma (ASX: QRX) has announced a collaboration agreement with Aesica Pharmaceuticals subsidiary Aesica Formulation Development.
Phosphagenics releases results of investigation
24 July, 2013An independent investigation into irregularities in Phosphagenics’ accounts has revealed that $5.7 million has been misappropriated from the company over the past eight years.
NSW medical device companies receive funding
23 July, 2013The NSW government has announced $10.3 million over three years to support companies working in the medical device arena.
Expression of interest invited for TGA statutory advisory committees
23 July, 2013The Therapeutic Goods Administration (TGA) is seeking expressions of interest (EOI) from experts for various positions on a number of statutory advisory committees. These committees provide independent expert advice to the Minister for Health and to the TGA on specific scientific and technical matters, which aids the TGA’s regulatory decision-making and other regulatory processes.
Phylogica appoints new CEO
23 July, 2013Phylogica has named Richard Hopkins as its new CEO and director, commencing immediately.
Pharmaxis gets simplified PBS listing for Bronchitol
22 July, 2013 by Dylan Bushell-EmblingThe Pharmaceutical Benefits Advisory Committee has agreed to tweak the PBS reimbursement criteria for Pharmaxis’s (ASX:PXS) Bronchitol in cystic fibrosis.
Mesoblast gets $4.3m R&D Tax Incentive rebate
22 July, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has received a $4.3m Tax Incentive reimbursement for its FY12 Australian R&D and plans to plough the funds back into its MPC development programs.
TGA survey: regulation of commercial IVDs
18 July, 2013The Therapeutic Goods Administration (TGA) invites manufacturers and sponsors of commercially produced in vitro diagnostic medical devices (IVDs) supplied in (or exported from) Australia to take part in a survey about the progress of the transition to the new regulatory framework for IVDs, introduced in 2010 and taking full effect on 1 July 2014.
